生殖支原体感染的个体化治疗——将氟喹诺酮类耐药检测纳入临床诊疗
生殖支原体因抗菌药物耐药率惊人上升而成为新发全球健康威胁。虽已成功采用大环内酯类个体化治疗,但氟喹诺酮类耐药率上升及替代方案稀缺使治疗复杂化。本文讨论文献数据并提出,聚焦耐药突变缺失(即野生型序列和抗菌药物敏感性)的诊断可指导氟喹诺酮类治疗后的微生物学治愈判断,澳大利亚数据强烈支持该策略。
要点
- 氟喹诺酮类耐药率上升及替代方案稀缺使生殖支原体个体化治疗复杂化。
- 聚焦耐药突变缺失的诊断可指导氟喹诺酮类治疗后的微生物学治愈判断。
- 开发同时检测野生型和常见ParC突变Ser83Ile的分子检测可改善一线抗菌药物选择和管理。
核心结论
- 聚焦耐药突变缺失(即野生型序列和抗菌药物敏感性)的诊断在指导氟喹诺酮类抗菌药物后的微生物学治愈方面有明确作用,澳大利亚数据强烈支持该策略。
- 开发纳入标记以检测野生型和仅最常见ParC突变Ser83Ile的分子检测,可极大改善一线抗菌药物选择和管理、个体化治愈检测,并对生殖支原体感染患者的诊疗极为有用。
研究设计与样本
- 本文为Personal View,讨论文献中现有数据并强调围绕使用氟喹诺酮类进行个体化治疗的问题。
主要发现
- 生殖支原体因抗菌药物耐药率惊人上升而成为新发全球健康威胁。
- 虽已成功采用大环内酯类个体化治疗,但氟喹诺酮类耐药率上升及替代治疗方案稀缺使治疗复杂化。
- 围绕使用氟喹诺酮类进行个体化治疗的问题包括对聚焦纳入ParC氟喹诺酮类耐药突变以指导抗菌药物治疗的犹豫。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mycoplasma genitalium is an emerging global health threat, due to an alarming rise in antimicrobial resistance. Although individualised treatment approaches have been successfully adopted for macrolides, treatment is complicated by rising rates of fluoroquinolone resistance and by the scarcity of alternative treatment options. In this Personal View, we discuss the available data within the literature and highlight issues surrounding individualised treatment using fluoroquinolones, including the hesitation to focus on inclusion of ParC fluoroquinolone resistance mutations for guiding antimicrobial treatments. We propose that there is a clear role for diagnostics that focus on the absence of resistance mutations (ie, wild-type sequences and antimicrobial susceptibility) to inform microbial cure following fluoroquinolone antimicrobials, with Australian data strongly supporting this approach. The development of molecular tests that incorporate markers to detect both wild-type and only the most common ParC mutation, Ser83Ile, could greatly improve first-line antimicrobial selection and stewardship, individualise tests of cure, and be extremely useful in the care of patients with M genitalium infection.
引用
- Sweeney EL, Bradshaw CS, Murray GL, et al. Individualised treatment of Mycoplasma genitalium infection-incorporation of fluoroquinolone resistance testing into clinical care. Lancet Infect Dis. 2022. PMID: 35325618. doi:10.1016/S1473-3099(21)00629-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。